SCHEMBL20028889

SCHEMBL20028889

CC(C)(C)OC(=O)N1CCCC(F)(c2nc3cc(Br)ccc3o2)C1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 7/20 0.47
MTOR P42345 1/20 0.40
PIK3CA P42336 1/20 0.39
RORC P51449 1/20 0.38
BACE1 P56817 2/20 0.38
GPR119 Q8TDV5 3/20 0.37
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 2/20 0.36
SCD5 Q86SK9 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028690 1.00 USP30 (0.47) USP30MTORPIK3CARORCBACE1
SCHEMBL20028847 0.85 USP30 (0.46) USP30PIK3CARORCGPR119SCD5
SCHEMBL21145396 0.85 USP30 (0.43) USP30NPC1ALDH1A1RAB9ALMNA
SCHEMBL21145398 0.85 USP30 (0.43) USP30NPC1ALDH1A1RAB9ALMNA
SCHEMBL20028692 0.84 USP30 (0.41) USP30MTORPIK3CABACE1GPR119
SCHEMBL20028693 0.84 USP30 (0.41) USP30MTORPIK3CABACE1GPR119
SCHEMBL20028691 0.82 USP30 (0.50) USP30MTORPIK3CAGPR119SCD5
SCHEMBL28779045 0.82 USP30 (0.50) USP30MTORPIK3CAGPR119SCD5
SCHEMBL20028892 0.81 USP30 (0.66) USP30PIK3CAGPR119
SCHEMBL23411511 0.81 GPR119 (0.47) MTORPIK3CABACE1GPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109790148-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-06-07 CN disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed
WO-2018060691-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 USP30 1/4885MTOR 2560/4885PIK3CA 3796/4885
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 USP30 1/4885MTOR 2560/4885PIK3CA 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.